HealthWizz, MintHealth Deploy Blockchain Technology for EHR’s
Blockchain, a technology invented in 2008 by the founder(s) of Bitcoin, has recently been the recipient of buzz regarding its potential use for electronic healthcare records. Healthcare data company Health Wizz has joined the trend, creating a blockchain-based platform for health records that allows users to access and share their own healthcare records. Company executives highlighted the ability of blockchain technology to improve the security and interoperability of electronic health records.
In a recent interview, CEO Raj Sharma pointed to a few key reasons why Health Wizz decided to utilize blockchain technology to power the platform.
One is the issue of security. “We as consumers are tired of trusting institutions with our data,” he said. “For us, it was really key that even when our consumers use our app, they don’t have to trust us. They have to trust blockchain.”
Additionally, Sharma noted that the startup wanted to create a marketplace of health data where pharmaceutical companies, research organizations and others can communicate with consumers. Blockchain was an ideal way to make these connections happen and allow groups to liaise even when they don’t trust each other.
Another electronic health record provider using blockchain technology is MintHealth:
Patients can access MintHealth online or via a mobile app. Each individual has a global identifier that allows them to access their information and oversee permissions to it. There are also payer-funded digital incentive tokens called vidamints, which patients receive when they partake in healthy behaviors. They can then use the tokens to help pay for healthcare-related costs.
Sharma described Health Wizz’ priorities for the future:
First, Health Wizz wants to make its tools easy to use and therefore attractive to consumers. The second step, which the company has already started, is normalizing the data so other people can access it. Finally, about a year down the road, the startup wants to have four or five pharma or clinical trial companies interacting with its consumers.
“If a few hundred end users are participating in clinical trials, that would be really what we would call success,” Sharma said.